| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
ZVRA
Zevra Therapeutics
|
Jun 09, 2026 | BUY |
Strong Buy
+87.6% avg upside
15 analysts
|
$29.00
129.20% Upside
|
-7.7% |
|
TARS
Tarsus Pharmaceuticals
|
May 07, 2026 | BUY |
Strong Buy
+19.8% avg upside
16 analysts
|
$90.00
41.54% Upside
|
-0.3% |
|
ATAI
Atai Beckley N.V.
|
Apr 16, 2026 | BUY |
Strong Buy
+229.6% avg upside
16 analysts
|
$16.00
294.99% Upside
|
-2.0% |
|
GHRS
GH Research
|
Mar 09, 2026 | BUY |
Strong Buy
+64.7% avg upside
11 analysts
|
$34.00
53.93% Upside
|
+50.1% |
|
PMN
ProMIS Neurosciences
|
Feb 05, 2026 | BUY |
Strong Buy
+575.0% avg upside
6 analysts
|
$35.00
227.79% Upside
|
-17.6% |
|
HELP
Helus Pharma
|
Dec 03, 2025 | BUY |
Strong Buy
+846.2% avg upside
12 analysts
|
$48.00
889.60% Upside
|
· |
|
OTLK
Outlook Therapeutics
|
Aug 28, 2025 | HOLD |
Buy
+414.6% avg upside
11 analysts
|
— | +45.0% |
|
IMVT
Immunovant
|
Aug 11, 2025 | BUY |
Strong Buy
+3.5% avg upside
24 analysts
|
$44.00
15.51% Upside
|
+135.2% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.